Human promyelocytic leukemia cells (HL60 ATCC CCL-240) and chronic myelogenous leukemia (K562 ATCC CCL-243) were purchased from ATCC and authenticated by STR repeats (Biosynthesis, Lewisville TX). Cell lines were grown in a maintenance medium culture: RPMI medium, supplemented with fetal bovine serum (20% in HL60, HMC and 10% in K562 cells), 1% penicillin-streptomycin, these were incubated at 37 °C in a humidified 5% CO2 atmosphere. The Human Mononuclear Cells (HMC) were obtained from hematologically normal patients undergoing orthopedic surgery. The procedures were performed at the Hematology Department, Medical Specialties Hospital, La Raza Medical Center IMSS, Mexico City, and the Hip Surgery Department, Villa Coapa Hospital, IMSS, Mexico City, respectively. The HMC were isolated using Ficoll Paque Plus (Pharmacia Biotech, Uppsala, Sweden). Cells were then resuspended in RPMI advanced medium and total numbers of nucleated and viable cells were determined with a hemocytometer, using Turck solution and trypan blue stain, respectively. HMC were collected according to institutional guidelines, including written informed consent from each donor.
All procedures were approved by the Ethics and Scientific Committee at IMSS with number R-2013-3602-6 (15 (link)).